Unknown

Dataset Information

0

COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.


ABSTRACT: Cyclooxygenase type-2 (COX-2) is overexpressed in malignant tumours including breast cancers, though the mechanism of upregulation is unclear. This study aimed to determine COX-2 expression in ductal carcinoma in situ (DCIS) in comparison to invasive breast cancer (IBC) and normal breast, and also to investigate the relationship of COX-2 expression with HER-2 expression, oestrogen receptor (ER), tumour grade and cellular proliferation (Ki67) in DCIS. Cyclooxygenase type-2, HER-2, ER and Ki67 expression were determined by immunohistochemistry on paraffin tissue sections of DCIS (n=187), IBC (n=65) and normal breast reduction tissue (n=60). Cyclooxygenase type-2 expression in DCIS (67%, P<0.001) and IBC (63%, P<0.001) was significantly greater than in normal breast (23%). There was no difference in COX-2 expression level between DCIS and IBC (P=0.87) or between normal breast from reduction mammoplasty tissue and normal breast ducts around DCIS (22%, P=0.29). In DCIS, COX-2 expression was associated with higher cellular proliferation rates (P<0.0001), nuclear grade (P=0.003), with ER negativity (P=0.003) and with HER-2 positivity (P<0.0001). Cyclooxygenase type-2 expression is upregulated in in situ breast cancer and is associated with surrogate markers of an aggressive DCIS phenotype including nonoestrogen-regulated signalling pathways. Cyclooxygenase type-2 inhibition may potentially prevent the development of ER-positive and ER-negative breast cancers.

SUBMITTER: Boland GP 

PROVIDER: S-EPMC2409574 | BioStudies | 2004-01-01

SECONDARY ACCESSION(S): 10.1038/sj.bjc.6601534

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6721358 | BioStudies
1000-01-01 | S-EPMC2864293 | BioStudies
2014-01-01 | S-EPMC4015460 | BioStudies
2019-01-01 | S-EPMC6717007 | BioStudies
1000-01-01 | S-EPMC4362647 | BioStudies
2013-01-01 | S-EPMC3875475 | BioStudies
2014-01-01 | S-EPMC4074093 | BioStudies
2020-01-01 | S-EPMC7299965 | BioStudies
1000-01-01 | S-EPMC3137418 | BioStudies
2020-01-01 | S-EPMC7640741 | BioStudies